Drug Trial Radar · NCT07308392
Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis
Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
119
Actual
Start
Feb 25, 2026
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase II clinical trial evaluating the efficacy and safety of HRS-7249 and SHR-1918 in patients with severe hypertriglyceridemia at high risk of acute pancreatitis
Conditions
- Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
Interventions
HRS-7249 injection setDrug
HRS-7249 injection set
SHR-1918 injection setDrug
SHR-1918 injection set
HRS-7249 injection placebo setDrug
HRS-7249 injection placebo set
SHR-1918 injection placebo setDrug
SHR-1918 injection placebo set
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in mean TG from baseline at weeks 44 and 48 of treatmentTime frame: at 44&48 weeks after the start of administration
- Proportion of subjects experiencing AP during the double-blind treatment periodTime frame: within 48 weeks after the start of administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.